Effentora (Fentanyl Buccal Tablet)

What Is Effentora and What Is It Used For?

Effentora belongs to a group of strong pain-relieving medicines called opioid analgesics. Its active substance, fentanyl, is a synthetic opioid that is approximately 50 to 100 times more potent than morphine. Fentanyl acts primarily on mu-opioid receptors in the brain and spinal cord to produce profound analgesia, sedation, and a sense of well-being.

Breakthrough cancer pain (BTcP) is a transient exacerbation of pain that occurs on a background of otherwise controlled persistent pain. It typically arises suddenly, reaches peak intensity within minutes, and may last from 30 to 60 minutes. Studies estimate that 50 to 89 percent of cancer patients with chronic pain experience breakthrough episodes, making effective rapid-onset treatments a critical component of comprehensive cancer pain management.

Unlike conventional oral opioids such as morphine tablets or oxycodone capsules, which must pass through the gastrointestinal tract and undergo first-pass metabolism in the liver, Effentora delivers fentanyl directly through the buccal mucosa (the inner lining of the cheek). This route bypasses first-pass metabolism, resulting in faster absorption and a more predictable onset of analgesia. The tablet uses a patented OraVescent technology, an effervescent reaction that temporarily lowers the local pH and then raises it, enhancing the proportion of un-ionized fentanyl available for transmucosal absorption.

Effentora was first approved by the European Medicines Agency (EMA) in 2008 and subsequently by the U.S. Food and Drug Administration (FDA). It is available exclusively by prescription and is classified as a Schedule II controlled substance in the United States, reflecting its high potential for abuse and dependence. In Europe and other jurisdictions, it is subject to special prescribing requirements for narcotic medications.

What Should You Know Before Taking Effentora?

Contraindications

There are several situations in which Effentora must absolutely not be used. Your prescribing physician will assess these before initiating treatment, but it is important for patients and caregivers to understand these restrictions.

• Opioid-naive patients: Effentora must never be used in patients who are not already receiving regular opioid therapy. The fentanyl dose in even the lowest strength tablet (100 mcg) can cause fatal respiratory depression in a person without established opioid tolerance.
• Severe respiratory depression: Patients with significant breathing difficulties, severe chronic obstructive pulmonary disease (COPD), or acute bronchial asthma should not take Effentora, as fentanyl further depresses respiratory function.
• Hypersensitivity: Effentora must not be used by anyone with a known allergy to fentanyl or any of the tablet's excipients, including mannitol, sodium starch glycolate, sodium bicarbonate, citric acid, or magnesium stearate.
• Severe hepatic impairment: Because fentanyl is primarily metabolized in the liver by the CYP3A4 enzyme system, severe liver disease can lead to dangerously elevated blood levels of the drug.
• Treatment of non-cancer pain: Effentora is not indicated and must not be used for acute pain, postoperative pain, headache, migraine, dental pain, or non-cancer chronic pain conditions.

Warnings and Precautions

Several conditions and circumstances require special caution when using Effentora. Your healthcare provider should be made aware of all your medical conditions before starting this medication.

• Respiratory depression: The most serious risk of Effentora is respiratory depression. This can occur at any dose, especially during the initial titration period. Patients should be closely monitored for signs of excessive sedation, slow or shallow breathing, and confusion.
• Head injuries and raised intracranial pressure: Fentanyl may obscure the clinical course of head injuries and can increase intracranial pressure in patients with brain tumours or other conditions affecting cerebrospinal fluid dynamics.
• Cardiac conditions: Fentanyl can cause bradycardia (slow heart rate) and hypotension (low blood pressure). Patients with pre-existing cardiac arrhythmias, heart failure, or electrolyte imbalances should be monitored carefully.
• Dependence and addiction: As a potent opioid, fentanyl carries a significant risk of physical dependence, psychological dependence, and addiction. Patients with a personal or family history of substance abuse disorder should be carefully assessed before treatment and closely monitored throughout.
• Oral mucositis: Patients undergoing cancer treatment frequently develop mouth sores (mucositis). This condition may increase the absorption rate of fentanyl from the buccal tablet, potentially leading to higher-than-expected blood levels and increased risk of adverse effects.
• Elderly patients: Older adults may be more sensitive to fentanyl's effects due to age-related changes in organ function, reduced lean body mass, and altered drug metabolism. Dose titration should proceed with particular caution.
• Renal impairment: Although fentanyl itself is primarily metabolized by the liver, patients with significant kidney disease may accumulate active metabolites and should be monitored accordingly.

Pregnancy and Breastfeeding

Effentora should not be used during pregnancy unless clearly necessary and only if the potential benefit justifies the potential risk to the fetus. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome, a potentially life-threatening condition in the newborn characterized by irritability, high-pitched crying, tremors, feeding difficulties, and seizures. This syndrome requires specialized neonatal care and can persist for days to weeks after birth.

Fentanyl is excreted in human breast milk and may cause sedation and respiratory depression in a nursing infant. Women should not breastfeed during treatment with Effentora and for at least 5 days after the last dose. If breastfeeding is being considered, the prescribing physician should carefully weigh the benefits of breastfeeding against the mother's need for Effentora and the potential adverse effects on the infant.

Women of childbearing potential should use effective contraception during treatment. The European Medicines Agency (EMA) and the FDA both classify fentanyl as a substance that should be used with extreme caution during pregnancy, and only when no safer alternatives are available for managing breakthrough cancer pain.

How Does Effentora Interact with Other Drugs?

Drug interactions with Effentora can be life-threatening. Because fentanyl is metabolized primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver and intestinal mucosa, any drug that inhibits or induces this enzyme can significantly alter fentanyl blood levels. Additionally, combining Effentora with other central nervous system (CNS) depressants poses a serious risk of profound sedation, respiratory depression, coma, and death.

Patients should always inform their healthcare provider of every medication they are taking, including prescription drugs, over-the-counter medicines, herbal products, and supplements. The following table summarizes the most clinically significant drug interactions.

Major Interactions

Minor Interactions

What Is the Correct Dosage of Effentora?

The dosing of Effentora follows a strict titration protocol. Unlike many medications where the starting dose is determined by the patient's body weight or severity of illness, Effentora dosing is entirely empirical. Every patient must begin titration at the lowest available dose (100 mcg), as there is no reliable way to predict the effective breakthrough pain dose from the maintenance opioid regimen. This is because the relationship between the around-the-clock opioid dose and the dose needed for breakthrough pain episodes is not linear or predictable.

Adults

The following outlines the standard adult dosing protocol as recommended by the EMA and FDA:

Children

Effentora is not approved for use in children or adolescents under 18 years of age. The safety and efficacy of transmucosal fentanyl products have not been established in the paediatric population for breakthrough cancer pain. The risk of fatal respiratory depression is particularly high in children due to their lower body weight and differing pharmacokinetic parameters. Any Effentora tablets in the household must be stored securely to prevent accidental exposure to children.

Elderly

Elderly patients (over 65 years) may be more sensitive to fentanyl due to age-related decreases in hepatic blood flow, reduced CYP3A4 activity, lower lean body mass, and altered protein binding. While no specific dose reduction is mandated, titration should be performed with particular caution, using longer intervals between dose adjustments and with heightened monitoring for respiratory depression and sedation. Clinical trials of Effentora included patients over 65, and while the overall safety profile was similar to younger adults, the incidence of certain adverse effects (particularly somnolence and confusion) was somewhat higher.

Missed Dose

Effentora is used on an as-needed basis for breakthrough cancer pain episodes and is not taken on a fixed schedule. Therefore, the concept of a "missed dose" does not apply. Patients should take Effentora only when a breakthrough pain episode occurs and should not take extra doses to compensate for untreated episodes. If the background pain is not adequately controlled, the around-the-clock opioid regimen should be reassessed rather than increasing the frequency of Effentora use.

Overdose

Fentanyl overdose is a medical emergency that can be rapidly fatal. The primary manifestation is respiratory depression, which may progress to respiratory arrest, circulatory depression, and death if not treated promptly.

The specific opioid antagonist naloxone is the primary treatment for fentanyl overdose. Because fentanyl has a longer duration of action than naloxone, repeated doses or a continuous infusion of naloxone may be necessary. Emergency medical services should be contacted immediately. In many countries, naloxone is available as a nasal spray (e.g., Narcan) for community use, and patients and their families may benefit from having it available in the home. If an overdose is suspected, remove any remaining tablet from the mouth before administering naloxone.

What Are the Side Effects of Effentora?

Like all opioid medications, Effentora can cause a range of side effects. Most are characteristic of the opioid drug class and relate to fentanyl's effects on the central nervous system, gastrointestinal tract, and cardiovascular system. Side effects are generally most common and most pronounced during the initial dose titration phase, and many patients develop a degree of tolerance to some effects (particularly nausea and sedation) over time. However, constipation tends to persist throughout treatment and usually requires prophylactic management.

The frequency of side effects is categorized according to international pharmacovigilance convention, based on data from clinical trials and post-marketing surveillance reported in the EMA Summary of Product Characteristics (SmPC) and FDA prescribing information.

Patients and caregivers should be aware that tolerance to the respiratory depressant effects of opioids can be lost rapidly if treatment is interrupted, even for a few days. If Effentora is restarted after a period of non-use, the patient should be re-titrated from the lowest dose, as their previous maintenance dose may now be dangerous.

How Should You Store Effentora?

Proper storage of Effentora is not merely a matter of maintaining drug potency; it is a critical safety measure. Fentanyl is an extremely potent opioid, and accidental exposure to even a single tablet can be lethal, particularly in children and other individuals who are not tolerant to opioids. The FDA has issued multiple warnings about paediatric deaths resulting from accidental exposure to transmucosal fentanyl products.

• Temperature: Store below 25°C (77°F). Do not freeze. Brief excursions to temperatures up to 30°C may be tolerated, but prolonged exposure to heat should be avoided.
• Packaging: Keep tablets in the original blister packaging until immediately before use. The blister provides protection from moisture and light, and also provides a child-resistant barrier.
• Security: Store Effentora in a locked cabinet, safe, or other secure location that is inaccessible to children, visitors, and anyone for whom the medication is not prescribed. Do not leave blister packs unattended on surfaces, in handbags, or in unlocked drawers.
• Disposal: Unused or expired Effentora tablets should be returned to a pharmacy for safe disposal through a medicine take-back programme. Do not flush tablets down the toilet unless no take-back option is available and the packaging specifically instructs you to do so. Do not discard in household rubbish where children or animals might access them.
• Shelf life: Do not use Effentora after the expiry date printed on the blister pack and outer carton. The expiry date refers to the last day of that month.

What Does Effentora Contain?

Each Effentora buccal tablet contains fentanyl as the active pharmaceutical ingredient, present in the form of fentanyl citrate. The actual amount of fentanyl citrate varies by strength, calculated to deliver the labelled amount of fentanyl base upon dissolution. The following details the composition of each strength:

Inactive Ingredients (Excipients)

The excipients in Effentora tablets serve specific pharmaceutical functions essential to the drug's delivery mechanism:

• Mannitol: A sugar alcohol used as a tablet filler and sweetener to improve palatability. Also functions as a bulking agent.
• Sodium starch glycolate (Type A): A disintegrant that helps the tablet break apart and dissolve when placed against the buccal mucosa.
• Sodium bicarbonate: One half of the effervescent couple. When combined with citric acid in the presence of moisture (saliva), it produces carbon dioxide gas, which temporarily alters the local pH and enhances fentanyl absorption through the mucosa.
• Citric acid (anhydrous): The other half of the effervescent reaction. The acid-base reaction with sodium bicarbonate is the core of the OraVescent delivery technology.
• Magnesium stearate: A lubricant used during tablet manufacturing to prevent the tablet material from sticking to the compression dies.

The tablets are white to off-white, flat-faced, round, with bevelled edges. Each strength is identified by a number debossed on one side corresponding to the dose in hundreds of micrograms (e.g., "1" for 100 mcg, "8" for 800 mcg). The tablets do not contain lactose, gluten, or any animal-derived ingredients.